SpineVision

SpineVision

Develops implants and instruments for treatment of spinal conditions.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
investor

€0.0

round
investor investor investor

€0.0

round
investor investor investor investor investor investor investor investor

€0.0

round
investor investor investor investor investor investor investor investor

€0.0

round
*

N/A

Merger
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2017201820192020202120222023
Revenues0000000000000000000000000000
% growth13 %5 %26 %-2 %--
EBITDA0000000000000000000000000000
% EBITDA margin(66 %)(41 %)(53 %)----
Profit0000000000000000000000000000
% profit margin(96 %)(85 %)(84 %)----
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article, Dealroom estimates

Notes (0)
More about SpineVision
Made with AI
Edit

SpineVision operates as a privately-owned medical device company, specializing in the design, development, and marketing of implants and instrumentation for spinal surgery. Established in 1999 and headquartered in France, the firm addresses approximately 90% of spinal pathologies, including degenerative disc diseases, deformities, cervical disorders, and trauma. In June 2024, SpineVision completed a merger with Clariance, now operating under the brand Clariance SpineVision, to enhance its market position and expand its global distribution to over 30 countries. The combined entity maintains headquarters in Lyon and Antony, France, with subsidiaries in the US and Italy.

The company's business model centers on in-house research and development, conducted in collaboration with orthopedic and neurosurgeons, while outsourcing production. This approach has led to a portfolio of over 20 patents. SpineVision generates revenue by selling its comprehensive suite of spinal treatment products to its primary clients: orthopedic surgeons and neurosurgeons. The company's strategy initially focused on creating a complete line of spinal products to compete with market leaders. More recently, it has emphasized a combination of dynamic stabilization and minimally invasive surgery. The firm has raised a total of $36.1 million over four funding rounds, with the latest being a Series B round in 2013.

A key product is the Hexanium TLIF cage, a titanium 3D-printed implant for spine fusion surgery that has received both FDA clearance and CE Mark approval. This product features a honeycomb-like structure and a roughened titanium surface to promote rapid osseointegration and reduce the risk of post-operative subsidence. Other notable products include the Flex+2 dynamic stabilization system and the LUMIS minimally invasive system. The company leverages 3D printing not only for prototyping, which accelerates development and improves communication with surgeons, but also for producing small series of titanium parts on demand, optimizing the supply chain. The current CEO is Arnaud Brisard, who brings over 20 years of experience from technology and defense sectors at companies like Alcatel and Netasq before joining SpineVision.

Keywords: spinal implants, medical devices, orthopedic surgery, spinal pathologies, minimally invasive surgery, dynamic stabilization, 3D-printed implants, spine fusion, neurosurgery, Clariance SpineVision

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by SpineVision

Edit